Genmab makes deal with J&J worth possible $1.1 billion

Rebecca Aris


Yesterday Genmab’s shares leapt 20% to 81 Danish kroner following the announcement of a global license and development agreement with Janssen potentially worth more than $1.1 billion.

The companies are to be collaborating on Genmab’s experimental cancer drug daratumumab, a human CD38 monoclonal antibody.

Genmab is currently running clinical trials of daratumumab as a treatment for multiple myeloma. In addition, it could potentially also be studied for acute myeloid leukemia and other types of cancer.

The agreement will mean that Janssen will have exclusive worldwide rights to develop and sell daratumumab.


Related news:

Genmab in potential $1B myeloma drug deal with J&amp,J (Businessweek?)

Genmab leaps on $1.1 billion daratumumab deal with Janssen (the pharma letter)


Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.